SecurityARLP / Alliance Resource Partners, L.P. (01877R108)
IndustryBituminous Coal and Lignite Surface Mining
Common Shares Outstanding130,903,256 shares (as of 2018-03-31)
Total Insiders18
Total Directors8
Total Officers9

Stock Insider Trading (from SEC Form 4)

Alliance Resource Partners, L.P. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

ARLP / Alliance Resource Partners, L.P. insiders include MGP II, LLC, NEAFSEY JOHN P, Alliance Resource Management GP, LLC, C-Holdings, LLC, CARTER NICK, and WESLEY CHARLES R, CANTRELL BRIAN L, Fouch Robert J, Alliance Holdings GP, L.P., SACHSE ROBERT G, Alliance GP, LLC, MARSHALL CARY P, Craft Kathleen S. Whelan Timothy J, CRAFT JOSEPH W III, Davis R Eberley, Torrence Wilson M, WYNNE THOMAS M, .

Insider Roster

Insider Dir Off 10% Shares Owned
Craft Kathleen S. 10% Owner
X 20,249,332
Alliance Holdings GP, L.P. 10% Owner
X 0
CANTRELL BRIAN L Senior VP and CFO
X 147,532
Davis R Eberley SVP-Law&Admin,General Counsel
X 90,493
CARTER NICK Director
X 17,781
SACHSE ROBERT G Excutive Vice President
X 147,773
Whelan Timothy J Senior Vice President Sales
X 23,226
CRAFT JOSEPH W III President and Chief Executive, Director, 10% Owner
X X X 170,603
WYNNE THOMAS M Senior Vice President and COO
X 251,291
Alliance GP, LLC Director, 10% Owner
X X 0
MGP II, LLC Director, 10% Owner
X X 0
WESLEY CHARLES R Executive Vice President, Director
X X 715,506
C-Holdings, LLC Director, 10% Owner
X X 0
Torrence Wilson M Director
X
NEAFSEY JOHN P Director
X
MARSHALL CARY P VP Corporate Finance
X
Alliance Resource Management GP, LLC 10% Owner
X 0
Fouch Robert J Vice President and Controller
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-05-31 4 C-Holdings, LLC D I -87,188,338 0
2018-05-31 4 WESLEY CHARLES R By Trust A I 715,506 715,506
2018-05-31 4 WESLEY CHARLES R By Trust A I 715,506 715,506
2018-05-31 4 WESLEY CHARLES R By Trust A I 1,035,729 1,035,729
2018-05-31 4 WESLEY CHARLES R By Trust A I 167,116 167,116
2018-05-31 4 WESLEY CHARLES R By Wesley Family LP A I 635,618 635,618
2018-05-31 4 WESLEY CHARLES R A D 1,035,728 1,035,728
2018-05-31 4 MGP II, LLC D D -56,100,000 0
2018-05-31 4 Alliance GP, LLC D D -87,188,338 0
2018-05-31 4 WYNNE THOMAS M By Wynne Family LP A I 251,291 251,291
2018-05-31 4 WYNNE THOMAS M By Trust A I 99,745 99,745
2018-05-31 4 WYNNE THOMAS M A D 660,816 735,976
2018-05-31 4 CRAFT JOSEPH W III Through spouse A I 168,603 170,603
2018-05-31 4 CRAFT JOSEPH W III A D 18,235,922 18,595,374
2018-05-31 4 CRAFT JOSEPH W III By Alliance Resource GP, LLC A I 1,343,348 1,352,529
2018-05-31 4 CRAFT JOSEPH W III By Alliance Holdings GP, L.P. D I -87,188,338 2,000
2018-05-31 4 Whelan Timothy J A D 3,003 23,226
2018-05-31 4 SACHSE ROBERT G A D 29,563 147,773
2018-05-31 4 CARTER NICK A D 14,781 17,781
2018-05-31 4 Davis R Eberley A D 11,086 90,493
2018-05-31 4 CANTRELL BRIAN L A D 39,171 147,532
2018-05-31 4 Alliance Holdings GP, L.P. See Foot Notes D I -56,100,000 0
2018-05-31 4 Alliance Holdings GP, L.P. D D -31,088,338 0
2018-02-08 4 WYNNE THOMAS M F D 20.40 -6,176 75,160
2018-02-08 4 WYNNE THOMAS M M D 19,038 81,336
2018-02-08 4 SACHSE ROBERT G F D 20.40 -6,152 118,210
2018-02-08 4 SACHSE ROBERT G M D 20,137 124,362
2018-02-08 4 CANTRELL BRIAN L F D 20.40 -4,157 108,361
2018-02-08 4 CANTRELL BRIAN L M D 13,424 112,518
2018-02-08 4 Davis R Eberley F D 20.40 -5,151 79,407
2018-02-08 4 Davis R Eberley M D 15,719 84,558
2017-08-07 4 NEAFSEY JOHN P P D 19.55 10,000 51,604 1,008,858
2017-07-28 4 Alliance Resource Management GP, LLC J D -56,100,000 0
2017-07-28 4 CRAFT JOSEPH W III By Alliance Resource GP, LLC J I 7,181 366,633
2017-07-28 4 CRAFT JOSEPH W III By Alliance Holdings GP, L.P. J I 56,100,000 87,547,790
2017-02-08 4 Davis R Eberley F D 23.25 -6,766 68,839
2017-02-08 4 Davis R Eberley M D 19,118 75,605
2017-02-08 4 MARSHALL CARY P F D 23.25 -3,667 20,969
2017-02-08 4 MARSHALL CARY P M D 10,684 24,636
2017-02-08 4 SACHSE ROBERT G F D 23.25 -7,224 104,225
2017-02-08 4 SACHSE ROBERT G M D 21,710 111,449
2017-02-08 4 WYNNE THOMAS M F D 23.25 -7,554 62,298
2017-02-08 4 WYNNE THOMAS M M D 21,118 69,852
2017-02-08 4 CANTRELL BRIAN L F D 23.25 -5,029 99,094
2017-02-08 4 CANTRELL BRIAN L M D 14,968 104,123
2017-02-08 4 Fouch Robert J F D 23.25 -2,118 36,980
2017-02-08 4 Fouch Robert J M D 5,856 39,098
2016-02-12 4 MARSHALL CARY P J D 15.24 564 13,952
2016-12-12 4 SACHSE ROBERT G G D -3,000 89,739
2016-08-03 4 Fouch Robert J S D 19.3358 -17,000 33,242 642,761
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

The U.S. Coal Miners That Could Gain From More Chinese Business - Bloomberg

2018-06-06 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (17-1)

Master Limited Partnership Simplifications On The Rise

2018-05-18 seekingalpha
The three only mark an acceleration of the trend of MLP "roll-ups," however. Many others have been announced in 2018. (43-0)

45 Basic Materials Wall St. Dividend Stars For May

2018-05-12 seekingalpha
Coal, Agribusiness, Chemicals, & Fibers topped May's Basic Materials sector 'WallStars' for gains, calculated by broker 1yr targets & 5/10/18. (29-1)

This Undervalued MLP Yields 11%-Plus And Just Smashed Earnings

2018-05-08 seekingalpha
Alliance Resource Partners yields over 11%, is growing its distribution, and just reported an impressive earnings beat. (6-0)

CORRECTED-BRIEF-Alliance Resource Partners Reports Quarterly Revenue of $457.1 Million

2018-04-30 reuters
* ALLIANCE RESOURCE PARTNERS, L.P. REPORTS INCREASES TO NET INCOME ATTRIBUTABLE TO ARLP AND EBITDA OF 48.6% AND 28.7%, RESPECTIVELY; RAISES QUARTERLY CASH DISTRIBUTION 1.0% TO $0.515 PER UNIT; AND INCREASES GUIDANCE (6-0)